Explore / Clinical trial
Clinical trial

Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults

Advanced Integrative Medical Science InstituteUnknownPhase 1Started Oct 1, 202312 enrolledUnited StatesNCT05894902

Abstract

Phase I safety and dose finding study of a standardized Ayahuasca analog (SM-001) in healthy adult volunteers

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

AyahuascaDepressionPTSD

Keywords

Banisteriopsis caapiPsychotria viridisethnomedicineN,N-dimethyltryptamine (DMT)harmine (HAR)harmalinetetrahydroharmineMajor DepressionPost Traumatic Stress Disorder
View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

This study's objects

Directly linked records, matched by DOI, trial reference, or registry, not just topic.

Publications from this trial

ArticleAyahuasca

The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network.

Palhano-Fontes F, Andrade KC, Tofoli LF +5

Europe PMC2015
ArticleAyahuasca

Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.

Hamill J, Hallak J, Dursun SM +1

Europe PMC2019

Related research

ArticlePsilocybin

Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.

Haridy R

Europe PMC2023
ArticlePsilocybin

Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.

Portes MAM, Bertoglio LJ

Europe PMC2026
PreprintKetamine

Blood biomarker changes in response to low-dose oral ketamine treatment in adults with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD)

Braxton AM, Driver C, Hermens DF +1

Europe PMC2026